drug · small molecule
GEMCITABINE HYDROCHLORIDE
Marketedupdated 5mo agoby $JNJ JOHNSON & JOHNSON🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 2Small molecule drug with a maximum clinical stage of Approval (across all indications), with 6 approved and 27 investigational indications.
indications
investigational
NSCLCBreast Cancer
targets
DNA polymerase (alpha/delta/epsilon)Ribonucleoside-diphosphate reductase RR1
all catalysts(3)
Trials studying GEMCITABINE HYDROCHLORIDE
- phase2A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
- phase3A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
- phase3Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- phase3A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
- phase3Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
- phase1Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
- phase3Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
- phase3A Study of SHR-A1811 in Subjects With Ovarian Cancer
Patent cliff
source: FDA Orange Bookfirst barrier falls
Sep 9, 2028
~1.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (15)
- Aug 19, 2034formulationUS 10729823
- Aug 19, 2034formulationUS 12447241
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Jul 1, 2033formulationUS 9241948
- Apr 15, 2032formulationUS 8679094
- Dec 17, 2030formulationUS 125762534.2y
- Jun 28, 2030formulationUS 124030863.7y
FDA exclusivities (1)
- Sep 9, 2028NPNP1.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that